高级搜索
李祥, 喻满成, 郑红梅, 张敏, 庄莹, 詹鹏, 吴新红. 2012—2015年湖北省男性乳腺癌发病与死亡分析[J]. 肿瘤防治研究, 2021, 48(11): 1012-1016. DOI: 10.3971/j.issn.1000-8578.2021.21.0615
引用本文: 李祥, 喻满成, 郑红梅, 张敏, 庄莹, 詹鹏, 吴新红. 2012—2015年湖北省男性乳腺癌发病与死亡分析[J]. 肿瘤防治研究, 2021, 48(11): 1012-1016. DOI: 10.3971/j.issn.1000-8578.2021.21.0615
LI Xiang, YU Mancheng, ZHENG Hongmei, ZHANG Min, ZHUANG Ying, ZHAN Peng, WU Xinhong. Incidence and Mortality of Male Breast Cancer in Hubei Province from 2012 to 2015[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1012-1016. DOI: 10.3971/j.issn.1000-8578.2021.21.0615
Citation: LI Xiang, YU Mancheng, ZHENG Hongmei, ZHANG Min, ZHUANG Ying, ZHAN Peng, WU Xinhong. Incidence and Mortality of Male Breast Cancer in Hubei Province from 2012 to 2015[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1012-1016. DOI: 10.3971/j.issn.1000-8578.2021.21.0615

2012—2015年湖北省男性乳腺癌发病与死亡分析

Incidence and Mortality of Male Breast Cancer in Hubei Province from 2012 to 2015

  • 摘要:
    目的 分析2012—2015年湖北省男性乳腺癌的发病及死亡情况。
    方法 收集2012—2015年湖北省肿瘤登记处上报的数据,将收集的数据按照年份、城乡及年龄别等作为分层因素,分析男性乳腺癌的发病率和死亡率变化趋势,对比男性和女性乳腺癌的发病及死亡差异。
    结果 2012—2015年湖北省共报告106例新发男性乳腺癌,发病率为0.43/105,女性10052例,发病率为42.76/105,男女发病率之比为1:99;男性乳腺癌死亡37例,死亡率为0.15/105,女性2201例,死亡率为9.36/105,男女死亡率之比为1:62。男女性乳腺癌发病率及死亡率不同年份、城乡之间存在差异。男性乳腺癌低发于年轻男性(< 35岁),35岁以后发病率随年龄增加而升高;男性乳腺癌死亡率在45岁以下的男性中较低,随着年龄增加死亡率也有所上升,男性乳腺癌发病率和死亡率高峰年龄为85岁以上男性。
    结论 男性乳腺癌在临床中少见,发病率远低于女性乳腺癌。即使如此,研究男性乳腺癌的发病率和死亡率的流行病学规律,能为男性乳腺癌的预防和治疗提供相应的参考。

     

    Abstract:
    Objective To analyze the incidence and mortality of male breast cancer in Hubei Province from 2012 to 2015.
    Methods The data reported by the Hubei Provincial Cancer Registry from 2012 to 2015 were collected for analyzing the incidence and mortality trends of male breast cancer according to year, urban and rural areas and age. We also compared the difference of incidence and mortality between male and female breast cancer.
    Results A total of 106 new cases of male breast cancer were reported in Hubei Cancer Registry from 2012 to 2015 with an incidence rate of 0.43/105, and 10052 new cases of female breast cancer with an incidence rate of 42.76/105; the male-to-female incidence ratio was 1:99. Male breast cancer death cases was 37 with the death rate of 0.15/105, and female breast cancer death cases was 2201 with the death rate of 9.36/105; the male-to-female mortality ratio was 1:62. The incidence and mortality of breast cancer between male and female varied by year, urban and rural areas. Male breast cancer was less common in young men (< 35 years old), and the incidence increased with age after 35 years old; male breast cancer deaths were rare in men under 45 years old, and the mortality rate increased with age. The incidence and mortality of male breast cancer patients over 85 years old reached the peak.
    Conclusion Male breast cancer is rare in clinical practice, and the incidence rate is much lower than that of female breast cancer. Even so, it is necessary to study the epidemiological law of male breast cancers' incidence and mortality, which can be used for prevention and treatment of male breast cancer.

     

/

返回文章
返回